Valvular heart disease associated with fenfluramine-phentermine
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Fenfluramine and phentermine have been individually approved as anorectic agents by the Food and Drug Administration (FDA). When used in combination the drugs may be just as effective as either drug alone, with the added advantages of the need for lower doses of each agent and perhaps fewer side effects. Although the combination has not been approved by the FDA, in 1996 the total number of prescriptions in the United States for fenfluramine and phentermine exceeded 18 million. METHODS: We identified valvular heart disease in 24 women treated with fenfluramine-phentermine who had no history of cardiac disease. The women presented with cardiovascular symptoms or a heart murmur. As increasing numbers of these patients with similar clinical features were identified, there appeared to be an association between these features and fenfluramine-phentermine therapy. RESULTS: Twenty-four women (mean [+/-SD] age, 44+/-8 years) were evaluated 12.3+/-7.1 months after the initiation of fenfluramine-phentermine therapy. Echocardiography demonstrated unusual valvular morphology and regurgitation in all patients. Both right-sided and left-sided heart valves were involved. Eight women also had newly documented pulmonary hypertension. To date, cardiac surgical intervention has been required in five patients. The heart valves had a glistening white appearance. Histopathological findings included plaque-like encasement of the leaflets and chordal structures with intact valve architecture. The histopathological features were identical to those seen in carcinoid or ergotamine-induced valve disease. CONCLUSIONS: These cases arouse concern that fenfluramine-phentermine therapy may be associated with valvular heart disease. Candidates for fenfluramine-phentermine therapy should be informed about serious potential adverse effects, including pulmonary hypertension and valvular heart disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Early weight loss medications, such as fenfluramine (Fen-Phen) and sibutramine, were withdrawn due to severe cardiovascular and psychiatric side effects [3,4].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [3]
In the citing paper
“While effective (average 10–15% weight loss), fenfluramine was withdrawn in 1997 after studies linked it to valvular heart disease and pulmonary hypertension [3].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [3]
In the citing paper
“While effective (average 10–15% weight loss), fenfluramine was withdrawn in 1997 after studies linked it to valvular heart disease and pulmonary hypertension [3].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [3]
In the citing paper
“Certainly, starvation, very-low-calorie diets, liquid protein diets, and obesity surgeries have been associated with prolongation of the QTc interval and increased risk of malignant dysrhythmias (1), and various pharmacologic agents have either limited efficacy or considerable toxicity (70 -72).”
From Obesity and Cardiovascular Disease (2009) · cites this paper as [70]
Citations
Cites
Appetite-suppressant drugs and the risk of primary pulmonary hypertension
Abenhaim, L., Moride, Y., Brenot, F., Rich, S., Benichou, J., Kurz, X., Higenbottam, T., Oakley, C., Wouters, E., Aubier, M., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608293350901 · Cited by 1,162
Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients.
Pellikka, P. A., Tajik, A. J., Khandheria, B. K., Seward, J. B., Callahan, J. A., Pitot, H. C., & Kvols, L. K. (1993) · Circulation · doi:10.1161/01.cir.87.4.1188 · Cited by 614
Robiolio, P. A., Rigolin, V. H., Wilson, J. S., Harrison, J. K., Sanders, L. L., Bashore, T. M., & Feldman, J. M. (1995) · Circulation · doi:10.1161/01.cir.92.4.790 · Cited by 406
Doppler Echocardiography: Theory, Instrumentation, Technique, and Application
NISHIMURA, R. A., MILLER, F. A., CALLAHAN, M. J., BENASSI, R. C., SEWARD, J. B., & TAJIK, A. J. (1985) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)60540-0 · Cited by 263
Primary pulmonary hypertension and fenfluramine use.
Brenot, F., Herve, P., Petitpretz, P., Parent, F., Duroux, P., & Simonneau, G. (1993) · Heart · doi:10.1136/hrt.70.6.537 · Cited by 251
Weir, E. K., Reeve, H. L., Huang, J. M. C., Michelakis, E., Nelson, D. P., Hampl, V., & Archer, S. L. (1996) · Circulation · doi:10.1161/01.cir.94.9.2216 · Cited by 218
Klein, A. L., Burstow, D. J., Tajik, A. J., Zachariah, P. K., Taliercio, C. P., Taylor, C. L., Bailey, K. R., & Seward, J. B. (1990) · Journal of the American Society of Echocardiography · doi:10.1016/s0894-7317(14)80299-x · Cited by 213
Valve Disease Associated with Ergot Alkaloid Use: Echocardiographic and Pathologic Correlations
Redfield, M. M., Nicholson, W. J., Edwards, W. D., & Tajik, A. J. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-1-50 · Cited by 156
Self-citationHormonal responses to fenfluramine in depressed and control subjects
Mitchell, P. B., & Smythe, G. A. (1990) · Journal of Affective Disorders · doi:10.1016/0165-0327(90)90008-v · Cited by 99
Irreversible pulmonary hypertension after treatment with fenfluramine.
McMurray, J. J. V., Bloomfield, P. M., & Miller, H. (1986) · BMJ · doi:10.1136/bmj.292.6515.239-a · Cited by 50
Research works printed but not linked: 4
- Heuer L, 1978, Chir Prax, 23, 497
- Tajik AJ, 1978, Mayo Clin Proc, 53, 271
- Thorson AH, 1958, Acta Med Scand Suppl, 334, 99
- Morita T, 1983, Am Rev Respir Dis, 127, 747
Cited by
Items 601–700 of 1,001
Proietto, J., Fam, B. C., Ainslie, D. A., & Thorburn, A. W. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.6.1317 · Cited by 36
Pharmacological Treatment of Obesity
Kabra, D. G., Kabra, U. D., Tschöp, M. H., & Hofmann, S. M. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3492-4_14 · Cited by 33
Lorcaserin Hcl for the treatment of obesity
Shukla, A. P., Kumar, R. B., & Aronne, L. J. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1096345 · Cited by 34
Milbank, E., Martínez, M. C., & Andriantsitohaina, R. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.11.002 · Cited by 33
“Very popular in the 1990’s owing to its demonstrated effectiveness on reducing body weight, Fen-Phen was withdrawn from the market in 1997 following numerous declared side effects linked to life-threatening such as pulmonary hypertension, and heart diseases (Connolly et al., 1997).”
BackgroundPrecision Medicine Approaches for Infantile-Onset Developmental and Epileptic Encephalopathies
Myers, K. A., & Scheffer, I. E. (2021) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-052120-084449 · Cited by 32
Agarwal, A., Farfel, G. M., Gammaitoni, A. R., Wong, P. C., Pinto, F. J., & Galer, B. S. (2022) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2022.05.006 · Cited by 31
Iribarren, C., Round, A. D., Peng, J. A., Lü, M., Zaroff, J. G., Holve, T. J., Prasad, A., & Stang, P. (2013) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3479 · Cited by 36
Dose Dependency and Reversibility of Serotonin-Induced Valvular Heart Disease in Rats
Droogmans, S., Roosens, B., Cosyns, B., Degaillier, C., Hernot, S., Weytjens, C., Garbar, C., Caveliers, V., Pipeleers-Marichal, M. A., Franken, P. R., et al. (2009) · Cardiovascular Toxicology · doi:10.1007/s12012-009-9046-2 · Cited by 32
The unrelenting fall of the pharmacological treatment of obesity
Dalmazi, G. D., Vicennati, V., Pasquali, R., & Pagotto, U. (2013) · Endocrine · doi:10.1007/s12020-013-9983-1 · Cited by 36
Polypharmacology and supercomputer-based docking: opportunities and challenges
Ellingson, S. R., Smith, J. C., & Baudry, J. Y. (2014) · Molecular Simulation · doi:10.1080/08927022.2014.899699 · Cited by 34
“[9–11] It has been demonstrated that animal studies during preclinical trial may not yield significant indications of these adverse interactions in humans [12], and such adverse effects are generally not discovered until a drug has reached clinical trial or is already on the market.”
BackgroundReforming Gendered Health Care: An Assessment of Change
Zimmerman, M. K., & Hill, S. A. (2000) · International Journal of Health Services · doi:10.2190/lyuv-qepa-4jbg-g184 · Cited by 31
“The life-threatening health problems to which women were exposed by their use of diet medications such as fenfluramine-phentermine (fen-phen) in the mid-1990s show how the health benefits of these procedures may prove minimal in the light of their possible adverse outcomes (60).”
BackgroundHagerman, R. J. (1999) · Mental Retardation and Developmental Disabilities Research Reviews · doi:10.1002/(sici)1098-2779(1999)5:4<305::aid-mrdd8>3.0.co;2-l · Cited by 34
Roth, J. D., & Rowland, N. E. (1998) · Psychopharmacology · doi:10.1007/s002130050598 · Cited by 31
“Indeed, as this study was completed, both FEN and DFEN were withdrawn from the market on the basis of possible adverse e¤ects on the cardiovascular system (Connolly et al. 1997).”
BackgroundUpdate on the Pharmacotherapy of Obesity
Cerulli, J., Lomaestro, B. M., & Malone, M. (1998) · Annals of Pharmacotherapy · doi:10.1345/aph.17039 · Cited by 32
Effect of GLP-1 receptor agonists on weight and cardiovascular outcomes: A review
Raza, F. A., Altaf, R., Bashir, T., Asghar, F., Altaf, R., Tousif, S., Goyal, A., Mohammed, A., Mohammad, M. F., Anan, M., et al. (2024) · Medicine · doi:10.1097/md.0000000000040364 · Cited by 37
“[24] Sibutramine, a serotonin and epinephrine uptake inhibitor, was approved the same year for appetite suppression; however, it was discontinued in 2010 after a post-marketing study revealed statistical evidence of increased stroke and MIs in patients with preexisting CVD or diabetes.”
BackgroundDérumeaux, G., Ernande, L., Sérusclat, A., Servan, E., Bruckert, É., ROUSSET, H., Senn, S. J., Gaal, L. V., Picandet, B., Gavini, F., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038273 · Cited by 32
New advances in models and strategies for developing anti-obesity drugs
Kim, G. W., Lin, J. E., Blomain, E. S., & Waldman, S. A. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.792804 · Cited by 37
Lorcaserin: a novel serotonin 2C agonist for the treatment of obesity
Nigro, S. C., Luon, D., & Baker, W. L. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.794776 · Cited by 30
Value of Weight Reduction in Patients with Cardiovascular Disease
Artham, S. M., Lavie, C. J., Milani, R. V., & Ventura, H. O. (2010) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-009-0056-y · Cited by 30
“These agents were taken off the US market in 1997 when they were shown to have serious adverse CV effects [ 36 ].”
BackgroundAortic Valve Repair for Aortic Insufficiency: A Review
Prodromo, J. P., D’Ancona, G., Amaducci, A., & Pilato, M. (2012) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2011.07.014 · Cited by 30
Identification of natural products as novel ligands for the human 5-HT2C receptor
Peng, Y., Zhao, S., Wu, Y., Cao, H., Xu, Y., Liu, X., Shui, W., Cheng, J., Zhao, S., Shen, L., et al. (2018) · Biophysics Reports · doi:10.1007/s41048-018-0047-1 · Cited by 30
Hayes, A. R., Davar, J., & Caplin, M. E. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2018.04.012 · Cited by 34
Blanck, H. M., Khan, L. K., & Serdula, M. K. (2004) · Preventive Medicine · doi:10.1016/j.ypmed.2004.04.040 · Cited by 30
Reeve, H. L., Nelson, D. P., Archer, S. L., & Weir, Ε. K. (1999) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.1999.276.2.l213 · Cited by 33
“In 1996, it was reported that the total number of prescriptions for the anorexic combination of fenfluramine and another anorexic agent, phentermine (Fen-Phen), was .18 million in the United States (8).”
BackgroundInfluentialApolipoprotein E ε4 and clinical phenotype in schizophrenia
Pickar, D., Malhotra, A. K., Rooney, W., Breier, A. F., & Goldman, D. A. (1997) · The Lancet · doi:10.1016/s0140-6736(05)63266-7 · Cited by 30
Drug treatment of obesity: don’t throw the baby out with the bath water
Bray, G. A. (1998) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/67.1.1 · Cited by 30
The big fat bariatric bandwagon
Pinkney, J. H., Johnson, A. B., & Gale, E. A. M. (2010) · Diabetologia · doi:10.1007/s00125-010-1845-2 · Cited by 33
“Worse still, the pharmacology of obesity has been littered with therapeutic disasters, most notoriously Fen-Phen—a combination of fenfluramine and phentermine—which induced valvular lesions of the heart and fatal pulmonary hypertension [ 5 , 6].”
BackgroundHeart Valve Disorders and Appetite-Suppressant Drugs
Jick, H. (2000) · JAMA · doi:10.1001/jama.283.13.1738 · Cited by 30
Application of Negative Design To Design a More Desirable Virtual Screening Library
Yang, Z., He, J.-H., Lü, A., Hou, T., & Cao, D. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01476 · Cited by 33
Lorcaserin for the treatment of obesity
Redman, L. M., & Ravussin, É. (2010) · Drugs of today · doi:10.1358/dot.2010.46.12.1556433 · Cited by 33
Management of obesity and cardiometabolic risk – role of phentermine/extended release topiramate
Caterson, I. D., Sweeting, A., Tabet, E. J., & Markovic, T. (2014) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s38979 · Cited by 36
Bariatric Surgery and Work-Up of the Massive Weight Loss Patient
Sebastian, J. L. (2007) · Clinics in Plastic Surgery · doi:10.1016/j.cps.2007.08.004 · Cited by 31
Current pharmacotherapeutic concepts for the treatment of obesity in adults
Idelevich, E. A., Kirch, W., & Schindler, C. (2009) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944708098226 · Cited by 33
“For instance, reported concerns about unacceptable side-effects, such as regurgitant valvular lesions of the heart [Connolly et al. 1997], led to the withdrawal of dexfenfluramine and fenfluramine from the market in September 1997 [Centers for Disease Control and Prevention, 1997].”
BackgroundCardiac Valvulopathy Associated with Pergolide Use
Zadikoff, C., Rochon, P. A., & Lang, A. E. (2006) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100004650 · Cited by 29
Scruggs, S. M., Disatian, S., & Orton, E. C. (2010) · Journal of Veterinary Cardiology · doi:10.1016/j.jvc.2010.06.002 · Cited by 29
Antiobesity pharmacotherapy in the management of Type 2 diabetes
Scheen, A. J., & Lef�bvre, P. J. (2000) · Diabetes/Metabolism Research and Reviews · doi:10.1002/(sici)1520-7560(200003/04)16:2<114::aid-dmrr97>3.0.co;2-o · Cited by 32
Rahimtoola, S. H., & Frye, R. L. (2000) · Circulation · doi:10.1161/circ.102.suppl_4.iv-24 · Cited by 29
Endoscopic vertical band gastroplasty with an endoscopic sewing machine
Awan, A. N., & Swain, C. P. (2002) · Gastrointestinal Endoscopy · doi:10.1067/mge.2002.120889 · Cited by 29
Supplemental Studies for Cardiovascular Risk Assessment in Safety Pharmacology: A Critical Overview
Picard, S., Goineau, S., Guillaume, P., Henry, J., Hanouz, J., & Rouet, R. (2011) · Cardiovascular Toxicology · doi:10.1007/s12012-011-9133-z · Cited by 29
Efficacy comparison of medications approved for chronic weight management
Kumar, R. B., & Aronne, L. J. (2015) · Obesity · doi:10.1002/oby.21093 · Cited by 29
Barriers and Solutions for Prescribing Obesity Pharmacotherapy
Fujioka, K., & Harris, S. R. (2020) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2020.02.007 · Cited by 28
Higgins, G. A., Desnoyer, J., Niekerk, A. V., Silenieks, L. B., Lau, W., Thevarkunnel, S., Izhakova, J., DeLannoy, I., Fletcher, P. J., DeLay, J., et al. (2014) · Pharmacology Research & Perspectives · doi:10.1002/prp2.84 · Cited by 30
Shen, M., Bellaousov, S., Hiller, M., de la Grange, P., Creamer, T. P., Malina, O., Sperling, R., Mathews, D. H., Stoilov, P., & Stamm, S. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt063 · Cited by 28
Emerging drugs for the treatment of obesity
Martinussen, C., Bojsen-Møller, K. N., Svane, M. S., Dejgaard, T. F., & Madsbad, S. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2017.1269744 · Cited by 28
Role of echocardiography in toxic heart valvulopathy
Droogmans, S., Kerkhove, D., Cosyns, B., & Camp, G. V. (2009) · European Journal of Echocardiography · doi:10.1093/ejechocard/jep023 · Cited by 28
Effects of a Novel Y5 Antagonist in Obese Mice: Combination With Food Restriction or Sibutramine
Mashiko, S., Ishihara, A., Iwaasa, H., Moriya, R., Kitazawa, H., Mitobe, Y., Itô, J., Gomori, A., Matsushita, H., Takahashi, T., et al. (2008) · Obesity · doi:10.1038/oby.2008.223 · Cited by 28
Investigational therapies in the treatment of obesity
Mancini, M. C., & Halpern, A. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.8.897 · Cited by 31
Elangbam, C. S., Colman, K., Lightfoot, R. M., Tyler, R. D., & Wall, H. G. (2002) · Toxicologic Pathology · doi:10.1080/01926230290105703 · Cited by 28
Imaging and Diagnostic Testing
Ekery, D., Davidoff, R., Orlandi, Q. G., Apstein, C. S., Hesselvik, J. F., Shemin, R. J., & Shapira, O. M. (2003) · American Heart Journal · doi:10.1016/s0002-8703(02)94786-1 · Cited by 30
Evidence in Upheaval: Incorporating Observational Data Into Clinical Practice
Ray, J. G. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.3.249 · Cited by 30
Kaddoumi, A., Nakashima, M. N., & Nakashima, K. (2001) · Journal of Chromatography B Biomedical Sciences and Applications · doi:10.1016/s0378-4347(01)00368-1 · Cited by 28
Michelakis, E. D., Weir, Ε. K., Nelson, D. P., Reeve, H. L., Tolarová, S., & Archer, S. L. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35220-6 · Cited by 28
The science of psychedelic medicine
Siegel, J. S., Liston, C. M., Nicol, G. E., Carhart-Harris, R. L., & Bogenschutz, M. P. (2026) · Nature Medicine · doi:10.1038/s41591-025-04194-5 · Cited by 28
Diseases of the Cardiovascular System
Lockhart, P. B., & Sun, Y. (2021) · Wiley eBooks · doi:10.1002/9781119597797.ch14 · Cited by 32
An Updated Approach to Antiobesity Pharmacotherapy: Moving Beyond the 5% Weight Loss Goal
Enright, C., Thomas, E., & Saxon, D. R. (2023) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac195 · Cited by 32
Restrictive organic mitral regurgitation associated with benfluorex therapy
Tribouilloy, C. M., Ruşinaru, D., Henon, P., Tribouilloy, L., Leleu, F., Andréjak, M., Sevestre, H., Peltier, M., & Caus, T. (2010) · European Journal of Echocardiography · doi:10.1093/ejechocard/jeq027 · Cited by 29
Cardiovascular Risks and Benefits of Medications Used for Weight Loss
Bramante, C. T., Raatz, S. J., Bomberg, E. M., Bensignor, M. O., & Ryder, J. R. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00883 · Cited by 27
“One such example is the combined use of fenfluramine and phentermine, which was associated with an increased development of valvular heart disease and pulmonary hypertension (3).”
BackgroundCellular pathology of mitral valve prolapse
Prunotto, M., Caimmi, P. P., & Bongiovanni, M. (2009) · Cardiovascular Pathology · doi:10.1016/j.carpath.2009.03.002 · Cited by 27
“[43]), the appetite suppressant co-therapy of fenfluramine and phentermine [44,45] (for review see Ref.”
BackgroundQuantitative analysis of human heart valves
McDonald, P. C., Wilson, J. E., Gao, M., McNeill, S., Spinelli, J. J., Williams, O. D., Harji, S., Kenyon, J. A., & McManus, B. M. (2002) · Cardiovascular Pathology · doi:10.1016/s1054-8807(02)00110-2 · Cited by 27
“When the therapeutic combination of fenfluramine (fen) and phentermine (phen) was linked by investigators at the Mayo Clinic in Fargo, ND to regurgitation of both mitral and aortic valves [1], pharmaceutical companies rapidly and voluntarily withdrew fen and dexfenfluramine (dexfen) from the market.”
BackgroundInfluentialObezite: Nedenleri ve tedavi seçenekleri
Altunkaynak, B. Z., Özbek, E., & Bilgiler, G. (2006) · Dicle Medical Journal / Dicle Tip Dergisi · Cited by 112
Cleary, L., Buber, R., & Docherty, J. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)02305-1 · Cited by 31
Bray, G. A. (2005) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2004.09.009 · Cited by 29
Weissman, N. J., Tighe, J. F., Gottdiener, J. S., & Gwynne, J. T. (1999) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00445-3 · Cited by 27
Rowland, N. E., Marshall, M., & Roth, J. D. (2000) · Psychopharmacology · doi:10.1007/s002139900336 · Cited by 27
Anorectic efficacy of the fenfluramine/phentermine combination in rats: additivity or synergy?
Roth, J. D., & Rowland, N. E. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00235-6 · Cited by 27
What Have We Learned From the Calcium Channel Blocker Controversy?
Califf, R. M., & Kramer, J. M. (1998) · Circulation · doi:10.1161/01.cir.97.16.1529 · Cited by 28
Epidemiology of Obesity and Pharmacologic Treatment Options
Shettar, V., Patel, S., & Kidambi, S. (2017) · Nutrition in Clinical Practice · doi:10.1177/0884533617713189 · Cited by 26
Identification of piperazine-bisamide GHSR antagonists for the treatment of obesity
Yu, M., Lizarzaburu, M. E., Beckmann, H., Connors, R., Dai, K., Haller, K., Li, C., Liang, L., Lindström, M., Ma, J., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.01.043 · Cited by 26
Vroonen, L., Lancellotti, P., Garcia, M. T., Dulgheru, R., Rubio-Almanza, M., Maiga, I., Magné, J., Pétrossians, P., Auriemma, R. S., Daly, A., et al. (2016) · Endocrine · doi:10.1007/s12020-016-1120-5 · Cited by 28
“reported a series of 24 cases of unusual valvulopathy in patients treated with fenfluramine and phentermine, two anorectic drugs frequently used in the USA at the time [17].”
BackgroundPast and present of antiobesity agents: Focus on monoamine modulators
Khorassani, F., Misher, A. D., & Garris, S. (2015) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp140034 · Cited by 27
“Most of these agents have been removed from the market in the United States due to safety concerns despite demonstrated efficacy in enhancing weight loss.(18-29) Fenfluramine derivatives.”
BackgroundNew psychoactive substances—Synthetic stimulants
Varì, M. R., Pichini, S., Giorgetti, R., & Busardò, F. P. (2018) · Wiley Interdisciplinary Reviews Forensic Science · doi:10.1002/wfs2.1197 · Cited by 30
Pregnancy outcomes after first trimester exposure to phentermine/fenfluramine
Jones, K. L., Johnson, K. A., Dick, L. M., Felix, R. J., Kao, K. K., & Chambers, C. (2002) · Teratology · doi:10.1002/tera.10023 · Cited by 26
Medical Therapy for Obesity—Current Status and Future Hopes
Bray, G. A. (2007) · Medical Clinics of North America · doi:10.1016/j.mcna.2007.06.013 · Cited by 27
Elangbam, C. S., Wehe, J. G., Barton, J. C., Krull, D., Nyska, A., Crabbs, T. A., & Kissling, G. E. (2006) · Experimental and Toxicologic Pathology · doi:10.1016/j.etp.2006.08.001 · Cited by 26
The combination of phentermine and fenfluramine reduced cocaine withdrawal symptoms in an open trial
Kampman, K. M., Rukstalis, M. R., Pettinati, H. M., Muller, E., Acosta, T., Gariti, P., Ehrman, R., & O’Brien, C. P. (2000) · Journal of Substance Abuse Treatment · doi:10.1016/s0740-5472(99)00076-8 · Cited by 26
Neurochemical mechanisms of phentermine and fenfluramine: Therapeutic and adverse effects
Rothman, R. B., & Baumann, M. H. (2000) · Drug Development Research · Cited by 26
A review of late-stage CNS drug candidates for the treatment of obesity
Heal, D. J., Gosden, J., & Smith, S. L. (2012) · International Journal of Obesity · doi:10.1038/ijo.2012.26 · Cited by 29
Accelerated publication versus usual publication in 2 leading medical journals.
Ghali, W. A., Cornuz, J., McAlister, F. A., Wasserfallen, J., Devereaux, P. J., & Naylor, C. D. (2002) · Europe PMC (PubMed Central) · Cited by 25
Seeking satiety: From signals to solutions
Tschöp, M. H., & Friedman, J. M. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adh4453 · Cited by 30
Nihalani, N. D., Schwartz, T. L., Siddiqui, U. A., & Megna, J. L. (2011) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2011.00232.x · Cited by 32
Medications for Obesity: Mechanisms and Applications
Bray, G. A. (2009) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2009.05.014 · Cited by 30
25CN‐NBOH: A Selective Agonist for in vitro and in vivo Investigations of the Serotonin 2A Receptor
Märcher-Rørsted, E., Jensen, A. A., & Kristensen, J. L. (2021) · ChemMedChem · doi:10.1002/cmdc.202100395 · Cited by 25
Nordexfenfluramine causes more severe pulmonary vasoconstriction than dexfenfluramine
Hong, Z., Olschewski, A., Reeve, H. L., Nelson, D. P., Hong, F., & Weir, Ε. K. (2004) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00247.2003 · Cited by 26
“Dex was withdrawn from the market in 1997 after it was found to cause carcinoid-like heart valve lesions (5, 23).”
BackgroundRasmussen, V. G., Poulsen, S. H., Dupont, E., Østergaard, K., Safikhany, G., & Egeblad, H. (2007) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2007.01874.x · Cited by 25
Association between selective serotonin-reuptake inhibitor therapy and heart valve regurgitation
Mast, S. T., Gersing, K. R., Anstrom, K. J., Krishnan, K. R., Califf, R. M., & Jollis, J. G. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01435-7 · Cited by 25
2. Recommendations on obesity and weight loss
Leiter, L. A., Abbott, D., Campbell, N. R. C., Mendelson, R., Ogilvie, R. I., & Chockalingam, A. (1999) · Canadian Medical Association Journal · Cited by 25
Kaddoumi, A., Nakashima, M. N., Maki, T., Matsumura, Y., Nakamura, J., & Nakashima, K. (2003) · Journal of Chromatography B · doi:10.1016/s1570-0232(03)00231-9 · Cited by 26
Roberts, W. C. (2004) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2004.11927961 · Cited by 25
Zhu, Z., Bolt, E., Newmaster, K. T., Osei-Bonsu, W., Cohen, S. R., Cuddapah, V. A., Gupta, S. S., Paudel, S., Samanta, D., Dang, L. T., et al. (2022) · Children · doi:10.3390/children9101507 · Cited by 28
Efficacy and Safety of Fenfluramine in Epilepsy: A Systematic Review and Meta-analysis
Damavandi, P. T., Fabin, N., Giossi, R., Matricardi, S., Giovane, C. D., Striano, P., Meletti, S., Brigo, F., Trinka, E., & Lattanzi, S. (2023) · Neurology and Therapy · doi:10.1007/s40120-023-00452-1 · Cited by 25
5-HT2C Receptor Stimulation in Obesity Treatment: Orthosteric Agonists vs. Allosteric Modulators
Przegaliński, E., Witek, K., Wydra, K., Kotlinska, J. H., & Filip, M. (2023) · Nutrients · doi:10.3390/nu15061449 · Cited by 25
2B Determined: The Future of the Serotonin Receptor 2B in Drug Discovery
Bender, A. M., Parr, L. C., Livingston, W. B., Lindsley, C. W., & Merryman, W. D. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01178 · Cited by 24
Al-Sahli, W., Ahmad, H., Kheradmand, F., Connolly, C., & Docherty, J. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)01070-6 · Cited by 25
Medications for Weight Reduction
Bray, G. A. (2008) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2008.08.004 · Cited by 25
“This combination became very popular,(86) but due to reports of aortic valvular regurgitation associated with its use, fenfluramine was withdrawn from the market worldwide on September 15, 1997.(87) Several other combinations of existing drugs are under development.”
BackgroundManagement of the obese patient undergoing office-based oral and maxillofacial surgery procedures
Chacon, G. E., Viehweg, T. L., & Ganzberg, S. I. (2003) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2003.07.004 · Cited by 24
Asymptomatic Mitral and Aortic Valve Disease Is Seen in Half of the Patients Taking ‘Phen-Fen'
Griffen, L., & Anchors, M. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.1.102 · Cited by 24
Diabesity: Are Weight Loss Medications Effective?
Halpern, A., & Mancini, M. C. (2005) · Treatments in Endocrinology · doi:10.2165/00024677-200504020-00001 · Cited by 27
Cho, B., Choi, J., Kang, H. J., Che, D., Shin, J. Y., Kim, J., Kim, S. G., & Jang, S. I. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.8493 · Cited by 23
A Narrative Review: Phentermine and Topiramate for the Treatment of Pediatric Obesity
Kim, A., Nguyen, J., Babaei, M., Kim, A., Geller, D. H., & Vidmar, A. P. (2023) · Adolescent Health Medicine and Therapeutics · doi:10.2147/ahmt.s383454 · Cited by 27
Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders
Rhee, T. G., Davoudian, P. A., Sanacora, G., & Wilkinson, S. T. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103818 · Cited by 24
Metadata
- Authors
- Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V.
- Affiliations
- Mayo Clinic (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1997-08-28
- Volume
- 337
- Issue
- 9
- Pages
- 581-588
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2134362869
- Cited by
- 1,632
- References
- 14
- Citations by year
- 2026: 23 · 2025: 23 · 2024: 26 · 2023: 43 · 2022: 32 · 2021: 40 · 2020: 35 · 2019: 39 · 2018: 42 · 2017: 55 · 2016: 54 · 2015: 58 · 2014: 51 · 2013: 55 · 2012: 59
- FWCI
- 72.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Valve Diseases and Treatments
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Issues in Pregnancy
- Keywords
- valvular heart disease, pulmonary hypertension, anorectic agents, women, adverse drug reactions
- MeSH terms
- Adult, Aortic Valve Insufficiency, Appetite Depressants, Drug Combinations, Female, Fenfluramine, Heart Valve Diseases, Humans, Hypertension, Pulmonary, Middle Aged, Mitral Valve, Mitral Valve Insufficiency, Phentermine, Tricuspid Valve Insufficiency, Ultrasonography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.